Lege Artis Medicinae

[Prevention and treatment of hepatic encephalopathy]

HUNYADY Béla

JUNE 15, 2012

Lege Artis Medicinae - 2012;22(05)

[As acute or chronic liver diseases progress, liver failure and related hepatic encephalopathy may develop. The latter occurs in more than 70% of patients with hepatic cirrhosis. Because of declining cognitive functions, sleep disturbances, memory problems and impaired motion coordination, this condition can - even in mild form - limit the patient's self-sufficiency and activity and can lead to a decreased quality of life and ability to work. Its most advanced stage, hepatic coma is one of the leading causes of liver-related mortality. These conditions generate a substantial healthcare costs. Treatment of hepatic encephalopathy involves dietary restrictions, prevention and treatment of precipitating factors, inhibition of the production and absorption of toxic substances (especially ammonia) and restoration of the amino acid balance. In addition to the traditionally used treatment with disaccharids (lactulose, lactitol), evidence has been accumulating regarding the efficacy and safety of a nonabsorbable antibiotic compound, rifaximin, which targets enteral pathogen bacteria, both in treatment and in prevention of hepatic encephalopathy. Artificial liver support therapies have been also introduced in Hungary. This review summarises the experience regarding treatment of hepatic encephalography for physicians involved in the management of patients with hepatic diseases.]

COMMENTS

0 comments

Further articles in this publication

Lege Artis Medicinae

[Dangers and Opportunities of Psychedelics – Part III ]

SZUMMER Csaba

Lege Artis Medicinae

[Quo vadis? Whose life is it anyway? EBM based health politics and health based politics]

KAPÓCS Gábor

Lege Artis Medicinae

[Thyroid hormone replacement in old age - practical advices]

SZABOLCS István

Lege Artis Medicinae

[Borderline and Stigmatisation An Interview with Éva Ratkóczi MD ]

NAGY Zsuzsanna

Lege Artis Medicinae

[Fulvestrant therapy in advanced osseal metastases]

MÉSZÁROS Edina, GALLER László, LANDHERR László

All articles in the issue

Related contents

LAM KID

[Alterations in bone metabolism associated with gastrointestinal diseases]

LŐRINCZY Katalin, LAKATOS Péter László, MIHELLER Pál, RÁCZ Károly

[Osteoporosis is commonly associated with certain gastrointestinal diseases. Osteoporosis occurs most often in patients with coeliac disease, inflammatory bowel disease, chronic liver disease and following gastric surgery. Prevention, diagnosis and therapy are based on the experiences with elderly and postmenopausal patients with osteoporosis. In this review, we summarise the clinical data regarding bone loss associated with gastrointestinal diseases.]

Lege Artis Medicinae

[CYCLIC RIFAXIMIN TREATMENT IN UNCOMPLICATED COLONIC DIVERTICULAR DISEASE - AN OPEN LABEL STUDY]

SIMON László, SALAMON Ágnes, FELFÖLDI Ferenc, TAM Beatrix, SÁNTA Judit, VADÁSZ Edit

[INTRODUCTION - Aquired diverticular disease of the colon is extremely common in developed countries. Poorly absorbing antibiotics may have beneficial effects on symptoms in long-term treatment. An open study was conducted to evaluate the efficiency of rifaximin in the prevention of complaints and recurrent diverticulitis. PATIENTS AND METHODS - Thirty consecutive patients with proven uncomplicated colonic diverticulosis were selected to receive rifaximin 200 mg bid for the first six days of every month, for six months. They were also advised to consume an high-fibre diet. Patients were reviewed on a monthly basis by clinical examinations; changes in symptom variables (lower abdominal pain, upper abdominal pain, bloating, tenesmus, diarrhoea, abdominal tenderness) were evaluated on a 10-point Visual Analogue Scale (VAS), and the presence of acute diverticulitis (abdominal mass, fever, US) was ruled out at every monthly visit. RESULTS - Twenty-nine of 30 patients completed the study. After six months of cyclic rifaximin treatment the global symptom score decreased in all patients compared to the baseline. Acute diverticulitis, other complications or side effects were not observed. CONCLUSIONS - In this open study cyclic administration of a relatively low dose of rifaximin in uncomplicated colonic diverticular disease resulted in the reduction of abdominal complaints and prevented recurrent diverticulitis. This effect might be explained by a reduced metabolic activity of intestinal bacterial flora.]

LAM Extra for General Practicioners

[SECONDARY OSTEOPOROSIS IN GASTROINTESTINAL DISEASES]

FUSZEK Péter

[Gastrointestinal disease is often overlooked or simply forgotten as a cause of osteoporosis. In a number of gastrointestinal diseases, sometimes because of the medicines used for their treatment, malabsorption syndrome may occur. Malabsorption might lead to insufficient absorption of calcium, phosphate, magnesium, vitamin D, vitamin K and proteins, which can cause osteopenia, osteoporosis and osteomalacia. In this paper, we aim to review the gastroenterological diseases that can lead to osteoporosis and treatment strategies.]

Lege Artis Medicinae

[RIFAXIMIN IN THE TREATMENT OF HEPATIC ENCEPHALOPATHY - A MULTICENTRIC STUDY]

SZALAY Ferenc, TELEGDY László, SZELI Dóra, CSÁK Tímea, FOLHOFFER Anikó, HORVÁTH Andrea, ABONYI Margit, SZABÓ Olga, RÉDEI Csaba, NEMESÁNSZKY Elemér

[INTRODUCTION - Hepatic encephalopathy is a well-known neuropsychiatric syndrome occurring in patients with either acute or chronic liver diseases. Rifaximin, a non-absorbable antibiotic is accepted for the treatment of hepatic encehalopathy. Our aim was to investigate the efficacy and the safety of rifaximin in cirrhotic patients with hepatic encephalopathy in Hungary. PATIENTS AND METHODS - 49 patients (25 male and 24 female) with hepatic encephalopathy stage I., II. and III. were involved into the study. Patients were treated with rifaximin for seven days. The daily dose was 3x400 mg in tablets. The severity of hepatic encephalopathy was characterised by hepatic encephalopathy index (HEi) calculated as a score of five parameters; mental state, asterixis, ammonia level, number connection test and critical flicker frequency. Pretreatment and postreatment HEi were compared. RESULTS - The study was completed in 46 patients. The treatment was suspended in 2 patients who died in liver failure and in one because of oesophageal variceal bleeding. The plasma ammonia level decreased from 103.7 ± 46.4 μmol/L to 67.7 ± 32.3 μmol/L (p=0,007) during the treatment. The hepatic encephalopathy index improved in 39 (85%) patients, worsened in 4 (9%) and no change was observed in 3 cases (6%). Improvement was observed in patients both with Child B and Child C stages. Loose stool in two patients and nausea in one patient were the only registered side effects. No severe adverse event related to the study medication was observed. CONCLUSIONS - Rifaximin is an effective and safe medicine for the treatment of hepatic encephalopathy.]

Lege Artis Medicinae

[Cirrhosis and its complications: diagnostic and treatment options]

PÁR Alajos

[During the past two decades, the management of complications of cirrhosis has dramatically changed, which substantially improved the patients’ survival. The present paper provides an overview of the diagnosis, treatment and prevention of cirrhosis and its complications including portal hypertension, variceal bleeding, ascites, hepatorenal and hepatopulmonary syndromes, encephalopathy and bacterial infection. Besides noninvasive diagnostic methods, pharmacological and endoscopic treatment modalities are discussed, with emphasis of the importance of nonselective beta-blockers, vasoactive therapy, antibiotic and albumin medication. Prevention and early diagnosis of cirrhosis as well as new pharmacological agents under development presumbaly result in further development in the management of patients with advanced, chronic liver disease.]